{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:31:18Z","timestamp":1786120278963,"version":"build-2736575974"},"reference-count":24,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2012,2]]},"DOI":"10.1097\/mcg.0b013e318228b5f6","type":"journal-article","created":{"date-parts":[[2011,8,3]],"date-time":"2011-08-03T17:06:46Z","timestamp":1312391206000},"page":"162-167","source":"Crossref","is-referenced-by-count":12,"title":["A Longitudinal Cohort Study of Mucocutaneous Drug Eruptions During Interferon and Ribavirin Treatment of Hepatitis C"],"prefix":"10.1097","volume":"46","author":[{"given":"Shahriar","family":"Tavakoli-Tabasi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ameena","family":"Bagree","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210305","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1056\/NEJM199908193410802","article-title":"The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.","volume":"341","author":"Alter","year":"1999","journal-title":"N Engl J Med"},{"key":"R2-13-20210305","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/S0140-6736(01)06102-5","article-title":"Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial.","volume":"358","author":"Manns","year":"2001","journal-title":"Lancet"},{"key":"R3-13-20210305","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1056\/NEJMoa020047","article-title":"Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection.","volume":"347","author":"Fried","year":"2002","journal-title":"N Engl J Med"},{"key":"R4-13-20210305","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM199811193392101","article-title":"Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C.","volume":"339","author":"McHutchison","year":"1998","journal-title":"N Engl J Med"},{"key":"R5-13-20210305","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1056\/NEJM199811193392102","article-title":"Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C.","volume":"339","author":"Davis","year":"1998","journal-title":"N Engl J Med"},{"key":"R6-13-20210305","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1046\/j.1365-2133.2002.04897.x","article-title":"Diffuse inflammatory lesions in patients treated with interferon alpha and ribavirin for hepatitis C: a series of 20 patients.","volume":"147","author":"Dereure","year":"2002","journal-title":"Br J Dermatol"},{"key":"R7-13-20210305","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1001\/archderm.135.8.1000","article-title":"High prevalence of cutaneous reactions to interferon alpha plus ribavirin combination therapy in patients with chronic hepatitis C virus.","volume":"135","author":"Sookoian","year":"1999","journal-title":"Arch Dermatol"},{"key":"R8-13-20210305","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1080\/000155501750376447","article-title":"Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus.","volume":"81","author":"Manjon-Haces","year":"2001","journal-title":"Acta Dermato-Venereologica"},{"key":"R9-13-20210305","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1097\/01.mcg.0000225599.24072.46","article-title":"Severe allergic eczema due to pegylated alpha-Interferon may abate after switching to daily conventional alpha-interferon.","volume":"41","author":"Veldt","year":"2007","journal-title":"J Clin Gastroenterol"},{"key":"R10-13-20210305","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1001\/archderm.140.2.215","article-title":"Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in patient with chronic hepatitis C virus infection.","volume":"140","author":"Moore","year":"2004","journal-title":"Arch Dermatol"},{"key":"R11-13-20210305","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1001\/archderm.141.1.102-b","article-title":"Generalized nummular eczema secondary to peginterferon alfa-2b and ribavirin combination therapy for hepatitis C infection.","volume":"141","author":"Shen","year":"2005","journal-title":"Arch Dermatol"},{"key":"R12-13-20210305","first-page":"11","article-title":"Atopic dermatitis: puzzles, insights, and progress.","volume":"21","author":"Hanifin","year":"2002","journal-title":"Dermatology Focus"},{"key":"R13-13-20210305","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1056\/NEJMcp0806464","article-title":"Seborrheic dermatitis.","volume":"360","author":"Naldi","year":"2009","journal-title":"N Engl J Med"},{"key":"R14-13-20210305","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1001\/archderm.1987.01660360066014","article-title":"A survey of skin problems and skin care regimens in the elderly.","volume":"123","author":"Beauregard","year":"1987","journal-title":"Arch Dermatol"},{"key":"R15-13-20210305","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1046\/j.1468-3083.2002.00378.x","article-title":"Pityriasis versicolor.","volume":"16","author":"Gupta","year":"2002","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R16-13-20210305","doi-asserted-by":"crossref","first-page":"692","DOI":"10.26719\/2009.15.3.692","article-title":"Skin manifestations of chronic hepatitis C virus infection in Cairo, Egypt.","volume":"15","author":"Raslan","year":"2009","journal-title":"East Mediterr Health J"},{"key":"R17-13-20210305","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1752-1947-1-86","article-title":"Extensive psoriasis induced by pegylated interferon: a case report.","volume":"1","author":"Citro","year":"2007","journal-title":"J Med Case Reports"},{"key":"R18-13-20210305","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1111\/j.1572-0241.2001.03735.x","article-title":"Angioedema after interferon therapy for chronic hepatitis C.","volume":"96","author":"Ohmoto","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"R19-13-20210305","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1046\/j.1365-2133.2003.05422.x","article-title":"Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection.","volume":"149","author":"Willems","year":"2003","journal-title":"Br J Dermatol"},{"key":"R20-13-20210305","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1111\/j.1572-0241.2005.00323.x","article-title":"Tongue and skin hyperpigmentation during PEG-interferon-alpharibavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C.","volume":"101","author":"Gurguta","year":"2006","journal-title":"Am J Gastroenterol"},{"key":"R21-13-20210305","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1111\/j.1572-0241.2007.01162.x","article-title":"Tongue hyperpigmentation in a Caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy.","volume":"102","author":"Torres","year":"2007","journal-title":"Am J Gastroenterol"},{"key":"R22-13-20210305","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1097\/00042737-199811000-00006","article-title":"A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis.","volume":"10","author":"Dalekos","year":"1998","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"R23-13-20210305","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.det.2006.06.002","article-title":"Inflammatory noninfectious dermatoses of HIV.","volume":"24","author":"Dlova","year":"2006","journal-title":"Derematol Clin"},{"key":"R24-13-20210305","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1053\/jhep.2001.21747","article-title":"Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C.","volume":"33","author":"Reddy","year":"2001","journal-title":"Hepatology"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00004836-201202000-00013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:21:37Z","timestamp":1786047697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-201202000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2]]},"references-count":24,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e318228b5f6","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2012,2]]}}}